SLC25A4 and cardiomyopathy: Moreover, the observed beneficial effect in the ant1-1 (RNAi) worm that can be considered similar to a knockout model suggests a potential therapeutic use of these molecules also for cardiomyopathies due to homozygous recessive mutations in ANT1.